Key Takeaways
- Semaglutide 2.4mg (Wegovy) produced ~15% average body weight loss over 68 weeks in the STEP 1 trial
- Tirzepatide 15mg (Zepbound) produced ~20.9% average body weight loss over 72 weeks in SURMOUNT-1
- In the head-to-head SURMOUNT-5 trial, 31.6% of tirzepatide patients lost ≥25% of body weight vs 16.1% on semaglutide
- Most patients see appetite changes within 2–4 weeks, visible weight loss by 8–12 weeks
- Up to 40% of weight lost can be lean muscle mass without resistance training — protecting muscle requires deliberate effort
If you've searched for "GLP-1 before and after," you've probably found two types of content: dramatic social media transformation photos with zero context, or clinical abstracts that are impossible to decipher. Neither is particularly useful for someone trying to decide whether to start treatment.
This guide uses data from published clinical trials — the most reliable "before and after" evidence available — to set realistic expectations for what GLP-1 medications can and cannot do.
The Numbers: Average Weight Loss by Medication
Semaglutide 2.4mg (STEP 1)
Tirzepatide 15mg (SURMOUNT-1)
on tirzepatide 15mg
on tirzepatide 15mg
For context, a person starting at 250 pounds could expect to lose approximately 37–38 pounds on semaglutide or 52–53 pounds on tirzepatide over about 16–18 months at the highest doses. These are averages — individual results vary significantly based on starting weight, diet, exercise, genetics, and dose titration.
Month-by-Month: What a Typical GLP-1 Journey Looks Like
The clinical trials tracked participants over 68–72 weeks. Here's what the trajectory typically looks like based on published data:
Weeks 1–4: The Adjustment Period
Appetite suppression begins within days for many patients. Nausea is common as your body adjusts. Weight loss is minimal (1–3 lbs) because you're on the lowest starter dose (2.5mg for both medications). This phase is about tolerability, not results.
Weeks 4–12: The Acceleration Phase
Doses increase through titration. Most patients notice meaningful appetite changes and reduced "food noise." Weight loss picks up to 1–2 lbs per week. This is where the "before and after" gap starts becoming visible — clothing fits differently, face shape may change.
Weeks 12–28: Peak Weight Loss Period
Patients are typically at or approaching their target dose. Weight loss rate is strongest during this window. Clinical trial data shows the steepest part of the weight loss curve occurs between months 3–7. Most patients have lost 8–12% of body weight by this point.
Weeks 28–52: Gradual Deceleration
Weight loss continues but slows. The body is adapting to lower caloric intake and reduced body mass. Some patients experience plateaus. This is normal — it doesn't mean the medication stopped working. Total weight loss typically reaches 12–18% of starting body weight.
Weeks 52–72+: Maintenance Zone
Weight loss reaches its maximum and stabilizes. For semaglutide, peak loss averaged ~15% at 68 weeks. For tirzepatide, ~20.9% at 72 weeks. Continued treatment is typically necessary to maintain results — clinical data shows significant regain (50–80% of weight lost) within 1–2 years of stopping.
What the "After" Photos Don't Show
The Muscle Question
Rapid weight loss from any source — medication, surgery, extreme dieting — involves some loss of lean muscle mass. Research suggests that without deliberate intervention (resistance training + high protein intake), up to 40% of weight lost on GLP-1 medications can be lean tissue rather than fat. This matters for metabolism, physical function, and long-term weight maintenance.
The practical takeaway: pair GLP-1 treatment with resistance training 2–3 times per week and aim for 0.7–1.0 grams of protein per pound of lean body mass daily. The BELIEVE trial studying bimagrumab + semaglutide found that the right combination could shift the ratio so that 92% of weight lost was fat rather than muscle.
The Skin Question
Losing 15–20% of body weight in 12–18 months is fast. Skin elasticity can't always keep pace, particularly for patients over 40 or those who started at higher body weights. "Ozempic face" — a more hollowed facial appearance — has become a widely discussed phenomenon, though it's a consequence of rapid fat loss, not a side effect of the medication itself.
The Sustainability Question
The STEP 1 Extension trial found that participants who stopped semaglutide regained approximately two-thirds of their lost weight within one year. GLP-1 medications treat obesity as a chronic condition — most patients need ongoing treatment to maintain results, similar to how blood pressure medication manages hypertension.
The "average" weight loss in clinical trials includes everyone — strong responders who lost 25%+ and modest responders who lost 5–8%. Your individual result will depend on factors including your starting BMI, metabolic health, lifestyle changes, and which medication you take. Most healthcare providers consider a ≥5% body weight loss clinically meaningful for health improvement.
Health Improvements Beyond the Scale
The most significant "before and after" changes often aren't visible in photos. Clinical trials have documented improvements in blood pressure, cholesterol profiles, blood sugar control, sleep apnea severity, joint pain, and cardiovascular risk markers. The SELECT trial demonstrated that semaglutide reduced major cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in patients with established heart disease — independent of weight loss.
What This Costs
The most common barrier to experiencing these results isn't eligibility — it's affordability. GLP-1 medications range from $99/month for compounded options to $1,350/month for brand-name prescriptions without insurance.
Compare GLP-1 Prices
See every provider's pricing side by side — compounded and brand-name options included.
Care Bare Rx — Affordable GLP-1 Programs
Compounded semaglutide with intake-focused onboarding. Straightforward process, competitive pricing.
We intentionally do not publish user-submitted before and after photos. Unverified transformation images can set unrealistic expectations, and there's no way to confirm what other interventions (surgery, extreme dieting, photo editing) may have contributed to the results. The clinical trial data above represents the most honest "before and after" evidence available — randomized, controlled, and measured over standardized timeframes.